The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients ...

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers. The investigational mRNA cancer immunotherapy is ...

Cartesian Therapeutics has a strong cash position after a $130 million equity raise, extending its runway to support upcoming ...

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.

Modernas new cancer vaccine, mRNA-4359, shows promising results in early clinical trials. Utilizing mRNA technology, similar ...

The technique is called in vivo CAR-M therapy. "The nomination of the two autoimmune targets is a significant milestone in ...

Moderna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer ...

Analyst Thomas Smith of Leerink Partners maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report), retaining the price ...

An experimental mRNA cancer vaccine shows promising results in a Phase 1 trial, potentially offering new hope for ...

Scientists from Spirovant Sciences describe SP-101, a novel adeno-associated virus (AAV) gene therapy for the treatment of ...

The trial is sponsored by Moderna. The mRNA immunotherapy is just one of many cancer vaccines entering clinical trials around the world. The therapy works by presenting common markers of tumours ...